Literature DB >> 19596483

Clinical significance of NQO1 C609T polymorphisms after postoperative radiation therapy in completely resected non-small cell lung cancer.

Si Yeol Song1, Seong-Yun Jeong, Heon Joo Park, Seung-Il Park, Dong Kwan Kim, Yong Hee Kim, Seong Soo Shin, Sang-Wook Lee, Seung Do Ahn, Jong Hoon Kim, Jung Shin Lee, Eun Kyung Choi.   

Abstract

PURPOSE: To investigate the clinical significance of NQO1 C609T polymorphisms to treatment outcome after postoperative radiation therapy in completely resected non-small cell lung cancer (NSCLC).
METHODS: One hundred and sixteen, Korean-ethnic, patients who were treated with surgery and postoperative radiation therapy from February 2000 to September 2005 in Asan Medical Center (Seoul, South Korea) were analyzed. All patients received 5040cGy radiation to surgical stump, mediastinum and ipsilateral supraclavicular node. NQO1 C609T polymorphisms were examined from a peripheral blood sample in all patients. Three types of NQO1 C609T polymorphisms were designated as C/C, C/T and T/T. Chest computed tomography was routinely checked after radiation therapy at every 3 or 6 months and locoregional tumor control, distant metastasis and survival by NQO1 C609T genotype were analyzed.
RESULTS: The proportion of NQO1 C609T polymorphisms was 27.6% for C/C, 53.4% for C/T and 19.0% for T/T. Most patients were men and had squamous cell carcinoma or adenocarcinoma. Median age of patients was 61 years. Major failure pattern was distant metastasis and 13 (11.2%) patients showed locoregional recurrence within the field of previous radiation therapy. Crude locoregional recurrence rate was significantly different by NQO1 genotype; 6.3% in C/C, 8.1% in C/T, and 27.3% in T/T (p=0.03), but distant metastasis was not different. Median follow-up time was 49.2 months (range: 3.4-103.5 months). Locoregional recurrence-free survival (LRRFS) was affected in T/T genotype compared with C/C or C/T genotype (p=0.01, Kaplan-Meier method), but distant metastasis-free survival (DMFS) or overall survival (OS) was not different by NQO1 genotype in univariate analysis. NQO1 genotype was also a significant factor for LRRFS (p=0.01) in multivariate analysis. Radiation-induced pneumonitis or esophagitis was tolerable in all patients and the difference by NQO1 genotype was not observed.
CONCLUSIONS: NQO1 C609T polymorphisms could be a predictive factor for the locoregional tumor control after postoperative radiation therapy in completely resected NSCLC. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19596483     DOI: 10.1016/j.lungcan.2009.06.009

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  6 in total

1.  Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer.

Authors:  Ho-Cheol Kim; Joon Seon Song; Jae Cheol Lee; Dae Ho Lee; Sang-We Kim; Jung-Shin Lee; Woo Sung Kim; Jin Kyung Rho; Sun Ye Kim; Chang-Min Choi
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

2.  The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer.

Authors:  Jill M Kolesar; Suzanne E Dahlberg; Sharon Marsh; Howard L McLeod; David H Johnson; Steven M Keller; Joan H Schiller
Journal:  Oncol Rep       Date:  2011-04-06       Impact factor: 3.906

Review 3.  Implications of NQO1 in cancer therapy.

Authors:  Eun-Taex Oh; Heon Joo Park
Journal:  BMB Rep       Date:  2015-11       Impact factor: 4.778

4.  NQO1 C609T polymorphism and lung cancer susceptibility: Evidence from a comprehensive meta-analysis.

Authors:  Jiawen Huang; Huiran Lin; Xiaosong Wu; Weijun Jin; Zhidong Zhang
Journal:  Oncotarget       Date:  2017-09-19

5.  NAD(P)H: quinone oxidoreductase 1 and NRH:quinone oxidoreductase 2 polymorphisms in papillary thyroid microcarcinoma: correlation with phenotype.

Authors:  Junguee Lee; Koon Soon Kim; Min Ho Lee; Yeon Soo Kim; Min Hee Lee; Seong Eun Lee; Yong Kyung Kim; Min Jeong Ryu; Soung Jung Kim; Min Jeong Choi; Young Suk Jo
Journal:  Yonsei Med J       Date:  2013-09       Impact factor: 2.759

6.  Increased NQO1 but not c-MET and survivin expression in non-small cell lung carcinoma with KRAS mutations.

Authors:  Ahmet Yilmaz; Nehad Mohamed; Kara A Patterson; Yan Tang; Konstantin Shilo; Miguel A Villalona-Calero; Michael E Davis; Xiaoping Zhou; Wendy Frankel; Gregory A Otterson; Howard D Beall; Weiqiang Zhao
Journal:  Int J Environ Res Public Health       Date:  2014-09-12       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.